在患有MYH9相关疾病的患者中使用eltrombopag成功移植
Aya Kato1, Yoko Shirai1, Shoichiro Kanda2
1Department of Pediatric Nephrology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan.
CEN case reports
|September 1, 2025
概括
接受移植的MYH9相关疾病患者可以避免危险的血小板输血. 在最近的一项病例研究中,预防性ELTROMBOPAG成功增加了血小板数量,防止了出血并发症.
科学领域:
- 肝脏病学
- 血液学
- 遗传学
背景情况:
- 与MYH9相关的疾病会导致大血缩,听力损失和功能衰竭,使移植复杂化.
- 这些患者的血小板减少会增加移植过程中的出血风险.
- 血小板输血可能导致与免疫接种并不能预防严重出血.
研究的目的:
- 在接受移植的MYH9相关疾病患者中报告eltrombopag的成功使用情况.
- 在此背景下评估eltrombopag在增加血小板数量和预防出血并发症方面的疗效.
主要方法:
- 一名患有MYH9相关疾病的19岁女性在移植前6周接受了预防性ELTROMBOPAG (TPO- RA).
- 在移植前和移植后监测血小板数量.
- 对出血并发症的临床结果进行了评估.
主要成果:
- 治疗Eltrombopag使患者的血小板数量从10×10^3/μL增加到156×10^3/μL.
- 在活体捐赠移植后,没有出现严重的术后出血并发症.
- 已经成功避免了血小板输血.
结论:
- 在患有MYH9相关疾病的移植患者中,术后使用eltrombopag是一种可行的策略.
- 在这些高风险患者中,Eltrombopag可能可以预防严重出血并避免需要血小板输血.
相关概念视频
01:28Kidney Transplant I: Introduction
60
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
60
01:26Kidney Transplant II: Surgical Procedure
75
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
75